Related Experiment Video
Updated: Jun 15, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design, Synthesis, and Hypoxia-Inducible Factor-1α Inhibitory Activity Evaluation of Panaxadiol Derivatives
Xin-Yu Ma1, Ming-Yue Li1, Kai-Han Jin1
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy, Yanji, 133000, China.
Abstract:
The hypoxia-inducible factor-1α (HIF-1α) pathway has been implicated in tumor angiogenesis, growth, and metastasis. Therefore, the inhibition of this pathway is an important therapeutic target for cancer. Thiazole derivatives have been reported to have diverse biological activities, especially in terms of anti-tumor. Consequently, we hypothesized that the introduction of a thiazole functional group in PD was likely to improve the biological potency. Here, three series of PD derivatives containing a thiazole moiety were synthesized, including (a) sulfonyl-containing thiazole derivatives (5 a-l), (b) urea-containing thiazole derivatives (7 a-i), and (c) thiourea-containing thiazole derivatives (9 a-i), and evaluated for HIF-1α inhibitory activity using a Hep3B cell-based luciferase reporter assay. The results showed that about 1/3 of the target compounds showed moderate or strong HIF-1α inhibitory activity, among which compounds 5 d and 7 b showed the strongest inhibitory activity with IC50 values of 17.37 and 6.42 μM, respectively, and did not show any significant cytotoxicity. Western blot assay results indicated that these two compounds exhibited more potent inhibition, compared with panaxadiol, of the expression of HIF-1α protein in Hep3B cells at a concentration of 50 μM. Molecular docking experiments were also performed to investigate the structure-activity relationship. Compounds 5 d and 7 b can be used as leads for further study and development of novel antitumor drugs.
Insights
New thiazole derivatives targeting the hypoxia-inducible factor-1α (HIF-1α) pathway show promise as anticancer agents. Compounds 5d and 7b demonstrated significant HIF-1α inhibition without cytotoxicity, offering potential for novel drug development.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- The hypoxia-inducible factor-1α (HIF-1α) pathway is crucial for tumor progression, making it a key therapeutic target.
- Thiazole derivatives possess known anti-tumor activities.
- Integrating thiazole moieties into existing drug scaffolds may enhance anti-cancer potency.
Purpose of the Study:
- To synthesize and evaluate novel thiazole derivatives for their ability to inhibit the HIF-1α pathway.
- To identify potent HIF-1α inhibitors with potential as anticancer therapeutics.
Main Methods:
- Synthesis of three series of thiazole derivatives: sulfonyl-, urea-, and thiourea-containing compounds.
- Evaluation of HIF-1α inhibitory activity using a Hep3B cell-based luciferase reporter assay.
- Western blot analysis and molecular docking to assess protein expression and structure-activity relationships.
Main Results:
- Approximately one-third of synthesized compounds exhibited moderate to strong HIF-1α inhibition.
- Compounds 5d and 7b displayed the most potent activity (IC50 values of 17.37 μM and 6.42 μM, respectively) without significant cytotoxicity.
- Western blot confirmed potent inhibition of HIF-1α protein expression by compounds 5d and 7b compared to panaxadiol.
Conclusions:
- Novel thiazole derivatives effectively inhibit the HIF-1α pathway.
- Compounds 5d and 7b represent promising lead compounds for the development of new anti-cancer drugs targeting HIF-1α.
- Further research and development are warranted for these potent inhibitors.
![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Antihypertensive Drugs: Vasodilators